Organization | Colorado Prevention Center

Colorado Prevention Center Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Aurora CO United States (1989)

Organization Overview

First Clinical Trial

2006

NCT00399919

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Colorado Prevention Center

Active Ingredients

Drugs in Phase 4 Trials (4)

cilostazol (pletal) (1 trial)

evolocumab (repatha) (1 trial)

levocarnitine (carnitor) (1 trial)

ranolazine (ranexa) (1 trial)

Drugs in Phase 3 Trials (6)

empagliflozin (jardiance) (1 trial)

finerenone (KERENDIA) (3 trials)

heparin (liquaemin) (1 trial)

propionyl l-carnitine (1 trial)

recombinant nematode anticoagulant protein c2 (1 trial)

rivaroxaban (xarelto) (1 trial)

Drugs in Phase 2 Trials (1)

tirasemtiv (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Angina Pectoris (Phase 4)

Intermittent Claudication (Phase 4)

Peripheral Arterial Disease (Phase 4)

Peripheral Vascular Diseases (Phase 4)

Vascular Diseases (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial APIs: 11